BPTH
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.03 | $0 | -$38,000 |
| 2025 Q4 | -0.03 | $0 | $0 |
| 2025 Q3 | -0.11 | $0 | $0 |
| 2025 Q2 | -0.55 | $0 | -$283,000 |
| 2025 Q1 | -0.40 | $0 | -$1M |
| 2024 Q4 | -1.15 | $158,000 | -$3M |
| 2024 Q3 | -0.70 | $0 | -$3M |
| 2024 Q2 | -1.16 | $0 | -$3M |